Outcomes of a network meta-analysis on systemic pharmacological treatments in chronic plaque psoriasis
In this medfyle
This updated 2023 Cochrane Review which compared the efficacy and safety of conventional systemic agents, small molecules, and biologics in moderate-to-severe psoriasis, by including 179 randomized clinical trials, found that biologics, and in particular infliximab, are the most beneficial therapeutic choices for achieving PASI 90 with no significant safety differences among them.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. PMID: 37436070; PMCID: PMC10337265.
The summary content was prepared by Medfyle, and reviewed by Martina Lambertini, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
